The estimated Net Worth of Stanley C Erck is at least $6.47 Milion dollars as of 14 December 2022. Mr. Erck owns over 6,966 units of Novavax stock worth over $476,999 and over the last 16 years he sold NVAX stock worth over $3,553,041. In addition, he makes $2,438,560 as President, Chief Executive Officer oraz Director at Novavax.
Stanley has made over 27 trades of the Novavax stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 6,966 units of NVAX stock worth $85,612 on 14 December 2022.
The largest trade he's ever made was selling 424,778 units of Novavax stock on 30 March 2016 worth over $2,204,598. On average, Stanley trades about 21,842 units every 93 days since 2008. As of 14 December 2022 he still owns at least 38,812 units of Novavax stock.
You can see the complete history of Mr. Erck stock trades at the bottom of the page.
Stanley C. Erck is President, Chief Executive Officer, Director of the Company. He was President and Chief Executive Officer of Novavax, Inc. since April 2011 and a Director since June 2009, and previously served as Executive Chairman from February 2010 to April 2011 and Interim Chief Financial Officer from November 2017 to March 2018. From 2000 to 2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG. He also previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International. Mr. Erck serves as a member of the boards of MaxCyte, Inc. and MDBio Foundation. Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago.
As the President, Chief Executive Officer oraz Director of Novavax, the total compensation of Stanley Erck at Novavax is $2,438,560. There are no executives at Novavax getting paid more.
Stanley Erck is 72, he's been the President, Chief Executive Officer oraz Director of Novavax since 2018. There are 2 older and 20 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.
Stanley's mailing address filed with the SEC is C/O NOVAVAX, INC., 21 FIRSTFIELD ROAD, GAITHERSBURG, MD, 20878.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi oraz Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: